Evidence map›Paper›PMID 39931620›Full record

ArticleCureus2025

A Financial Benefit-Cost Analysis of Advancing Jordan's Medical Tourism: The Case of Proton Therapy.

Ahmad N Fasseeh, Emad Almomani, Baher Elezbawy, Youssef H Ahmed, Kareem A El-Fass, Emad Alsharu, Zoltán Kaló

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmad N FasseehHealth Economics, Syreon Middle East, Alexandria, EGY.
Emad AlmomaniHealth Economics, Jordanian Royal Medical Services, Amman, JOR.
Baher ElezbawyEvidence Synthesis, Syreon Middle East, Alexandria, EGY.
Youssef H AhmedHealth Economics, Syreon Middle East, Alexandria, EGY.
Kareem A El-FassHealth Economics, Syreon Middle East, Alexandria, EGY.
Emad AlsharuReproductive Endocrinology, Jordanian Royal Medical Services, Amman, JOR.
Zoltán KalóHealth Economics, Syreon Research Institute, Budapest, HUN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives Jordan is moving forward toward enhancing medical tourism. Proton therapy (PT), an effective intervention for cancer treatment, is unavailable in some countries, often necessitating international travel to receive treatment. This study aims to evaluate the cost-benefit of establishing a PT facility in Jordan to address this gap. Our study is one of the first studies to evaluate the economic impact of medical tourism through establishing a PT facility, showing its potential to position Jordan as a regional hub for advanced medical care. Methods We conducted a financial benefit-cost analysis using an ex-ante analysis model. The analysis was conducted from two distinct perspectives: the healthcare payer perspective and the societal perspective. Model inputs were derived through a literature search and questionnaires completed by local experts. Deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) were used to assess model robustness and explore key uncertainties. To overcome uncertainty in projected user numbers, two scenarios were created: a conservative scenario with average capacity, and an optimistic scenario based on maximum device utilization. Results The benefit-cost ratio (BCR) of establishing the facility was 1.24 from the societal perspective. This perspective showed a net present value (NPV) of 15 million Jordanian dinars (JOD), an internal rate of return (IRR) of 12%, and a payback period of seven years. From the public payer perspective, values were less favorable, but still positive, with a BCR of 1.08, an NPV of 5 million JOD, an IRR of 6%, and a payback period of nine years. Scenario analyses showed that, if the device is utilized to its maximum capacity, the benefit would increase reaching BCRs of 1.80 and 1.58 from the societal and healthcare payer perspectives, respectively. DSA and PSA proved the robustness of the model results. Conclusions The model shows that establishing a PT facility in Jordan is cost-effective, and is expected to generate substantial economic returns, making it a justifiable investment decision.

Indexed as

benefit-cost ratiocost-benefit analysisinternal rate of returninvestmentjordanmedical tourismnet present valueproton therapy

Identifiers

PMID39931620
PMCPMC11809275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.